Le Lézard

News by subject: TRI

11 december 2023

07:30
Treatment with Auxoratm shown to potentially reduce the severity of asparaginase-associated pancreatitis, also called asparaginase-induced pancreatic toxicity, in pediatric patients with acute lymphoblastic leukemia Auxora eliminated the need for...

07:30
- Data collectively highlight revumenib's combination potential with current standard of care agents and support advancement into pivotal combination trials in the frontline setting - - 100% CRc observed in BEAT AML trial exploring revumenib in...

07:01
All 15 ibezapolstat-treated patients in Phase 2b who achieved Clinical Cure (CC) at end of treatment (EOT) remained free of C. difficile Infection (CDI) recurrence through one month after EOT, for a Sustained Clinical Cure (SCC) rate of 100% 2 of 14...

07:00
Hemab...

07:00
Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") , a Phase 2 clinical-stage biotechnology company, today announced updates for its two clinical programs, EP-104IAR, its lead drug candidate in development for the treatment of knee...

07:00
Mabwell (688062.SH), an innovative biopharmaceutical company with entire industry chain, announced that its submission to the Center for Drug Evaluation (CDE) of the National Medical Products Administration for the "A Randomized, Open-label,...

07:00
STRM.BIO, a pre-clinical, VC-backed biotechnology company that is leveraging extracellular vesicles (EVs) to deliver gene therapies and developing new therapeutics for rare blood diseases, presented the first preclinical data on their novel delivery...

07:00
HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," today announced the presentation of...

05:55
Laekna (2105.HK), a clinical-stage biotechnology company,...

00:14
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released the latest efficacy and safety data of...


10 december 2023

20:15
Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced long-term follow...

19:39
APPLY-PNH extension data show that continuous Fabhalta® (iptacopan) treatment in adults with paroxysmal nocturnal hemoglobinuria (PNH) enabled sustained hemoglobin-level increases to near-normal (?12 g/dL), blood transfusion avoidance, and improved...

19:30
Antengene Corporation Limited ("Antengene" SEHK: 6996.HK), a leading innovative,...

18:30
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the European Commission (EC) on December 7 approved VEOZATM (fezolinetant) 45 mg once daily for the treatment of moderate to severe vasomotor symptoms...

15:15
Taiho Oncology, Inc. announced results of a U.S. real-world...

13:30
Data on RPT1G, a clinical drug candidate for the treatment of solid and hematological malignancies, that selectively kills cancer cells and is thousands-fold better tolerated by healthy cells than previous NAMPT inhibitors.First presentation...

12:00
82% ORR and deep clinical responses from off-the-shelf, allogeneic BCMA-targeted CAR-T in heavily pretreated patients receiving adequate lymphodepletion 100% ORR in these patients who were not previously treated with a BCMA-targeted bispecific T...

10:45
Research findings being presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition highlight new treatment approaches that are enabling patients to live longer or better, judicious uses of older treatment approaches, and...

05:00
Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published in The Lancet Oncology and presented in oral session at the 65th American...


9 december 2023

21:20
Four studies presented during the 65th American Society of Hematology (ASH) Annual Meeting and Exposition examine how demographics and other characteristics of patients and researchers play into inequities in health outcomes in the context of blood...

20:10
Researchers report striking progress in the application of cutting-edge tools and treatments to address longstanding challenges in blood disorders and related health conditions in four studies presented during the 65th American Society of Hematology...

17:46
Servier, a leader in oncology committed to bringing the promise of tomorrow to the patients we serve, will be presenting new data in acute myeloid leukemia (AML) at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. These...

15:01
The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.  The work...

12:30
Blueprint Medicines Corporation today announced data showcasing its commitment to advance the scientific understanding and treatment of systemic mastocytosis (SM) at the 65th American Society of Hematology (ASH)...

12:00
AbbVie and Genmab A/S announced today that adult patients with relapsed/refractory (R/R) follicular...


8 december 2023

16:00
...

13:20
Jazz Pharmaceuticals...

13:18
Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved CRESEMBA® (isavuconazonium sulfate), an azole antifungal drug, for...

11:30
STORM Therapeutics Ltd. (STORM), the clinical stage biotechnology company discovering and developing novel small molecule therapies targeting...

09:59
Omeza®, a regenerative skincare company that develops marine-based therapies for the treatment of chronic wounds, today presented in vivo data showing that OCMtm alone...

09:48
This new post hoc analysis of the Phase 3 EMERALD trial evaluated elacestrant in the endocrine-sensitive population (CDK4/6 inhibitor duration of at least 12 months) with tumors harboring ESR1 mutations.This analysis shows a clinically meaningful...

09:20
With 5.6 months of additional follow-up and 78.3% of patients having completed Kisqali® (ribociclib) investigational treatment, the updated analysis shows sustained iDFS benefit and stability in secondary endpoints including overall survival...

09:00
The novel combination therapy with atezolizumab and bevacizumab added to chemotherapy as first-line treatment in the ATRACTIB trial demonstrates significant antitumor activity in in patients with advanced triple-negative breast cancerCohort 5 of...

09:00
Amgen today announced the...

08:30
SkylineDx, an innovative diagnostics company focused on research & development of molecular diagnostics is looking forward to the release of new data during the American Society of Hematology (ASH) 2023 Annual Meeting. Dr. Noa Biran, Associate...

08:30
INT230-6 demonstrated a systemic increase in the median diversity of T-cell repertoire in patients' blood compared to baseline that was also much larger than a control saline injection A single injection of INT230-6 can induce up to >95% necrosis...

08:00
Actinium Pharmaceuticals, Inc. (Actinium or the Company), a leader in the development of targeted radiotherapies, today...

07:00
ExeGi Pharma, a pioneering biopharmaceutical company dedicated to the development and commercialization of innovative live biotherapeutics, has announced the first patient enrollment in its landmark PROF Trial. The trial will study the potential of...

03:30
iOnctura, a clinical-stage biotech developing selective cancer therapies against...


7 december 2023

21:33
A randomised, double-blind, placebo-controlled trial (RECOVERY STUDY) conducted by The Chinese University of Hong Kong (CUHK)'s Faculty of Medicine (CU Medicine) and Microbiota I-Center (MagIC) showed that an oral microbiome microencapsulated formula...

18:39
...

18:00
Px HealthCare (Px), the digital health company behind the clinically-validated OWise cancer patient support app, announced today the presentation of a first-of-its-kind Real World Evidence (RWE) study at the San Antonio Breast Cancer Symposium...

13:57
A special report published today in the Association for Diagnostics & Laboratory Medicine's (ADLM's, formerly AACC's) The Journal of Applied Laboratory Medicine describes the design, operations, and methodology of the COVID Immunity Study, a...

13:00
Data from Phase 1 clinical trial in heavily pretreated patients with metastatic breast cancer showed DAN-222 was safe and well tolerated and demonstrated clinical activity as monotherapy and in combination with a PARP inhibitor DAN-222 is the first...

13:00
BioGenCell, a pioneer in personalized cell therapy solutions, is excited to announce the launch of its fifth Phase II...

12:30
GIE Medical, a clinical stage company developing solutions for patients suffering from benign stricture(s) of the esophagus or bowel, announced today that enrollment has begun in its Paclitaxel Coated Balloon for the Treatment of Chronic Benign...

09:00
Eli Lilly Canada Inc. is pleased to announce that Health Canada has authorized the label...

09:00
Bugworks Research Inc., a clinical-stage biopharmaceutical company, is presenting the research findings on its novel, best-in-class, dual-acting adenosine antagonists BWC2094 and BWC2562 with the potential to treat a variety of hard-to-treat cancers,...

09:00
Rivermark Medical, a company dedicated to developing a novel therapeutic device for benign prostatic hyperplasia (BPH), announced today the full enrollment of its RAPID-II clinical trial, a multi-center OUS clinical trial with sites in Australia, New...

09:00
Delcath Systems, Inc. , an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the publication of a clinical study in the journal...